The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
The untapped potential of ascites in ovarian cancer research and treatment
Open accessAbstract
The build-up of fluid in the peritoneal cavity-ascites-is a hallmark of ovarian cancer, the most lethal of all gynaecological malignancies. This remarkable fluid, which contains a variety of cellular and acellular components, is known to contribute to patient morbidity and mortality by facilitating metastasis and contributing to chemoresistance, but remains largely under-researched. In this review, we will critically analyse the evidence associating ascites with metastasis and chemoresistance in ovarian cancer and provide an update on research in the field. We will argue the case for ascites as a unique and accessible substrate for tracking tumour progression and for translational research that will enhance our understanding of this cancer and lead to improvements in patient outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They disseminate by forming aggregates of multicellular spheroids that float in malignant ascitic fluid alongside fibroblasts, adipocytes, mesothelial, endothelial and inflammatory cells, as well as cell-free DNA, before “seeding” onto new microenvironments and establishing metastatic deposits (Ford et al., 2020).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Ford et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M. W., Reinhard, F., Zhang, C. C., Shipitsin, M. V., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,839
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I. B., Trope, C. G., Amant, F. C., Kristensen, G. B., Ehlen, T., Johnson, N. P., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, Á. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,538
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H. Q., Mannel, R. S., Homesley, H. D., Fowler, J. M., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,413
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, É., Kristensen, G. B., Carey, M. S., Beale, P. J., Cervantes, A. M. R., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,181
Ovarian Cancer Development and Metastasis
Lengyel, E. R. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,702
Pujade-Lauraine, É., Hilpert, F., Weber, B. E., Reuß, A., Poveda, A. M., Kristensen, G. B., Sorio, R., Vergote, I. B., Witteveen, P. O., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,660
Cited by
Sorted by citations
Items 101–200 of 262
Miceska, S., Škof, E., Buček, S., Kuhar, C. G., Gašljević, G., Smrkolj, Š., & Prevodnik, V. K. (2023) · Radiology and Oncology · doi:10.2478/raon-2023-0046 · Cited by 9
Trevisi, E., Sessa, C., & Colombo, I. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00239 · Cited by 8
Cortesi, M., Warton, K., & Ford, C. E. (2024) · PeerJ · doi:10.7717/peerj.17603 · Cited by 8
Feng, Y., Zhang, Z., Yang, H., Miao, F., Li, Y., Zhang, M., Cao, Y., & Li, M. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70106 · Cited by 8
He, T., Zhang, J., Zeng, L., Yin, Z., Yu, B., Zhang, X., Yang, X., Shang, C., Xue, L., & Guo, H. (2025) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2025.01.06 · Cited by 8
Liu, Q., Feng, C., Wu, T., Zhang, S., Wang, X., Zhao, Q., Song, X., Liu, S., Quan, L., Zhang, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-67859-2 · Cited by 9
Chemoresistance in Ovarian Cancer: The Role of Malignant Ascites
Nunes, M., & Ricardo, S. A. V. (2022) · Exon Publications eBooks · doi:10.36255/exon-publications-ovarian-cancer-malignant-ascites · Cited by 8
Prediction model of adnexal masses with complex ultrasound morphology
Wu, Y., Miao, K., Wang, T., Xu, C., Yao, J., & Dong, X. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1284495 · Cited by 8
Herzog, M., Verdenik, I., Kobal, B., & Černe, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126780 · Cited by 8
Zhu, Y., Wang, C., Ma, Z., Li, F., Xu, C., Pan, W., & Liu, A. (2023) · Journal of Cancer · doi:10.7150/jca.83663 · Cited by 9
Proteomic Profiling of Bacterial Extracellular Vesicles for Exploring Ovarian Cancer Biomarkers
Asano‐Inami, E., Yokoi, A., Yoshida, K., Taki, K., Kitagawa, M., Suzuki, K., Uekusa, R., Nagao, Y., Yoshikawa, N., Niimi, K., et al. (2025) · Journal of Extracellular Biology · doi:10.1002/jex2.70073 · Cited by 7
Gerton, T. J., Green, A., Campisi, M., Chen, M., Gjeci, I., Mahadevan, N. R., Lee, C. A. A., Mishra, R., Vo, H. V., Haratani, K., et al. (2023) · Cancers · doi:10.3390/cancers15164128 · Cited by 8
Advances in the treatment of malignant ascites in China
Zhang, J., Qi, Z., Ou, W., Mi, X., Fang, Y., Zhang, W., Yang, Z., Zhou, Y. Y., Xiuying, L., Hou, J., et al. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-023-08299-w · Cited by 8
Herzog, M., Verdenik, I., Kobal, B., & Černe, K. (2025) · Scientific Reports · doi:10.1038/s41598-025-88707-9 · Cited by 7
Guo, L., Qin, X., Xue, L., Yang, J. Y., Zhang, Y., Zhu, S., Ye, G., Tang, R., & Yang, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.964076 · Cited by 7
A Subset of Secreted Proteins in Ascites Can Predict Platinum-Free Interval in Ovarian Cancer
Carroll, M. J., Kaipio, K., Hynninen, J., Carpén, O., Hautaniemi, S., Page, D. L., & Kreeger, P. K. (2022) · Cancers · doi:10.3390/cancers14174291 · Cited by 7
Kurelac, I., Sollazzo, M., Luise, M. D., Nanetti, F., Lanteri, L., D’Angelo, L., Cavina, B., Corrà, S., Miglietta, S., Milioni, S., et al. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1537407 · Cited by 6
McQuarter, A. A., Cruz, J., Yamauchi, C. R., Chouchen, M., Carter, C. S., Webb, T. J., & Khan, S. (2026) · Current Oncology · doi:10.3390/curroncol33010059 · Cited by 7
Li, N., Jiang, X., Ma, X., Qiu, X., Chang, H., Qiao, Y., Luo, H., & Zhang, Q. (2023) · Discover Oncology · doi:10.1007/s12672-023-00642-1 · Cited by 6
Cationic liposomes overcome neutralizing antibodies and enhance reovirus efficacy in ovarian cancer
Yang, Z., Chen, L., Guo, T., Huang, L., Yang, Y., Ye, R., Zhang, Y., Lin, X., Fan, Y., Gong, C., et al. (2024) · Virology · doi:10.1016/j.virol.2024.110196 · Cited by 6
Cosgrove, P. A., Bild, A. H., Dellinger, T. H., Badie, B., Portnow, J., & Nath, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247507 · Cited by 7
Han, H., Hou, D., Lin, Q., Hao, X., Zhang, Z., & Peng, X. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1623926 · Cited by 5
Venous thromboembolism in ovarian cancer: pathophysiology, risk, and management
Obeagu, E. I. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004192 · Cited by 5
Ascites protects against ferroptosis and enables the peritoneal growth of ovarian cancer
Setayeshpour, Y., Chen, S., Dayanidhi, D. L., Lee, Y. W., Wu, S.-C., Aristizabal‐Henao, J. J., Wu, J., Lin, C., Setayeshpour, N., Federico, C., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72116-1 · Cited by 5
Gorini, F., Coadǎ, C. A., Monesmith, S., Leo, A. D., de Biase, D., Dondi, G., Costanzo, S. D., Mezzapesa, F., Vannini, I., Melloni, M., et al. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01177-7 · Cited by 5
Cavarzerani, E., Caligiuri, I., Bartoletti, M., Corona, G., Perin, T., Palumbo, A., Ditto, A., Occhiali, T., Canzonieri, V., & Rizzolio, F. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.009 · Cited by 6
Pandraklakis, A., Prodromidou, A., Haidopoulos, D. A., Πασπάλα, Ά., Oikonomou, M. D., Machairiotis, N., Rodolakis, A., & Thomakos, N. (2022) · Cureus · doi:10.7759/cureus.26222 · Cited by 5
Skryabin, G. O., Komelkov, A. V., Жорданиа, К. И., Bagrov, D. V., Enikeev, A. D., Galetsky, S. A., Beliaeva, A. A., Kopnin, P., Moiseenko, A. V., Senkovenko, A. M., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070902 · Cited by 5
Duraki, D., Jabeen, M., Mao, C., Wang, L., Ghosh, S., Dai, X., Zhu, J., Boudreau, M. W., Nelson, E. R., Hergenrother, P. J., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217738 · Cited by 5
Jeong, M. J., Yoon, Y. N., Kang, Y. K., Kim, C. J., Nam, H.-S., & Lee, Y. S. (2023) · Cancers · doi:10.3390/cancers15082328 · Cited by 5
Manikam, N. R. M., Andrijono, A., Witjaksono, F., Kekalih, A., Sunaryo, J., Widya, A., & Nurwidya, F. (2024) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2024.25.2.555 · Cited by 5
Pisano, S., Jimenez, Y. S., Rees, P. C. T., Xiao, J., González, D., Conlan, R. S., & Corradetti, B. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07162-2 · Cited by 5
Scanlan, J., Mittal, P., Lokman, N. A., Oehler, M. K., Hoffmann, P., & Klingler‐Hoffmann, M. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00771 · Cited by 4
Uno, K., Yoshihara, M., Yamakita, Y., Kitami, K., Iyoshi, S., Sugiyama, M., Koya, Y., Kanayama, T., Sahara, H., Nomura, S., et al. (2026) · Science Advances · doi:10.1126/sciadv.adu5944 · Cited by 4
Grech, C. T., Aust, S., Hofstetter, G., Uhl, E., Hinterleitner, L., Grimm, C., Polterauer, S., & Pils, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-01917-z · Cited by 4
Takano, G. H. S., de Amorim, R. F. B., Ferreira, V. M. M., Vianna, L. M. D. S., de Castro, T. M. M. L., Carneiro, M. D. V., Oliveira, Í. D. A., Motoyama, A. B., & Carneiro, F. P. (2022) · PubMed Central · Cited by 4
Wang, J., Fang, X., Yang, J., Tang, Q., Yang, Y., Li, Z., Zhang, F., Wu, Q., Luo, Z., & Zheng, Z. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.135385 · Cited by 4
Werner, B., Sjoquist, K. M., Espinoza, D., Yip, S., Chang, G., Cummins, M. M., Mileshkin, L., Ananda, S. S., Shannon, C., Friedlander, M. L., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101914 · Cited by 4
Fridegren, J., Björkhem‐Bergman, L., Schultz, T., & Strang, P. M. (2024) · Journal of Palliative Medicine · doi:10.1089/jpm.2024.0140 · Cited by 4
Reversible downregulation of MYC in a spheroid model of metastatic epithelial ovarian cancer
Buensuceso, A. V., Borrelli, M. J., Valdés, Y. R., & Shepherd, T. G. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00850-z · Cited by 5
Iyoshi, S., Kimura, M., Yoshihara, M., Kunishima, A., Miyamoto, E., Fujimoto, H., Kitami, K., Mogi, K., Uno, K., Tano, S., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-13218-1 · Cited by 4
Ito, R., Kagabu, M., Sato, S., Takatori, E., Kaido, Y., Nagasawa, T., Shoji, T., Hirayama, T., Terao, Y., & Baba, T. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02682-1 · Cited by 4
Body location embedded 3D U-Net (BLE-U-Net) for ovarian cancer ascites segmentation on CT scans
Nag, M. K., Liu, J., Liu, L., Shin, S., Lee, S., Lee, J.-M., & Summers, R. M. (2023) · International Symposium on Medical Information Processing and Analysis (SIPAIM) · doi:10.1117/12.2669783 · Cited by 4
Liu, X., Lu, H., Zhou, Y. Y., Long, X., Li, Q., Zhuang, G., Yin, X., & Di, W. J. (2023) · Cancer Medicine · doi:10.1002/cam4.5853 · Cited by 4
Zhang, M., Bao, Y., Zhang, H., Li, D., Mei, X., & Cheng, X. (2023) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2023.2204940 · Cited by 4
Miceska, S., Škof, E., Gašljević, G., & Prevodnik, V. K. (2023) · Cells · doi:10.3390/cells12192390 · Cited by 4
Lin, J., Chen, L., Wu, D., Lin, J., Liu, B., & Guo, C. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/1372879 · Cited by 4
Biobanking and gynecologic oncology - Special considerations, challenges and opportunities
Grech, L., Grech, C. A., Calleja‐Agius, J., & Pace, N. P. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.109713 · Cited by 3
Gupta, R., Shravan, S., Agwane, S. B., Bankar, R., & Bapat, S. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-18264-8 · Cited by 3
Hypoxia induced VEGF secretion promotes resistance to bispecific T-cell engagers
Xu, M., Barakzai, S., Kumar, R., Veillard, I. E., Kim, E., Bregar, A. J., Eisenhauer, E. L., Penson, R. T., Bouberhan, S., Filipi, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02505-3 · Cited by 3
Spatial tumor evolution panorama of ovarian cancer
Feng, C., Yang, Y., Li, G., Fang, Z., Yang, B., Zhao, F., Chen, X., Liu, S., Wu, D., Hu, X., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102666 · Cited by 4
Li, S., Yang, L., & Zhu, Z. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-026-02150-6 · Cited by 3
Design of PI3K-mTOR Dual Inhibitors for Ovarian Cancer: Are we on the Right Track?
Mangala, S. S., Rathi, E., Udupa, K., Kabekkodu, S. P., Pai, K. S. R., & Kini, S. G. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673293028240326051835 · Cited by 4
Bischof, K., Cremaschi, A., Eroukhmanoff, L., Landskron, J., Flage‐Larsen, L., Gade, A., Bjørge, L., Urbanucci, A., & Taskén, K. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13726 · Cited by 3
Xie, G., Zhang, Y., Ma, J., Guo, X., Xu, J., Chen, L., Zhang, J., Li, Y., Zhang, B., & Zhou, X. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-789 · Cited by 3
Implication of fibroblast growth factor 7 in ovarian cancer metastases and patient survival
Mortan, L. F., Meelheim, B. A., Garland, J., Bohn, J. A., Isingizwe, Z. R., & Benbrook, D. M. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1524606 · Cited by 3
Kolendowski, B., Cheng, S., Valdés, Y. R., Shepherd, T. G., & DiMattia, G. E. (2025) · Cells · doi:10.3390/cells14110785 · Cited by 3
Addley, S., McGowan, M. A., Crossland, H., Johnson, A., Asher, V., Bali, A., Abdul, S., & Phillips, A. (2023) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2023.107078 · Cited by 3
Liu, C. C., Li, Y., Li, Y., Hu, M., Wang, H., Lu, S., Zhao, L., Dilimulati, D., Jiao, S., Lu, S., et al. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1143 · Cited by 3
Ivermectin Strengthens Paclitaxel Effectiveness in High-Grade Serous Carcinoma in 3D Cell Cultures
Nunes, M., & Ricardo, S. A. V. (2024) · Pharmaceuticals · doi:10.3390/ph18010014 · Cited by 3
Pregnancy is associated with the prognosis of ovarian cancer patients with abdominal metastasis
Cui, H.-T. (2025) · American Journal of Cancer Research · doi:10.62347/jujq9225 · Cited by 3
Canario, R., Ribeiro, A. S., Morgado, I., Peixoto, A., Barbosa, A., Santos, C., Mendes, N. M., Lopes, P., Monteiro, P., Coelho, R., et al. (2025) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-025-04104-7 · Cited by 2
Mortan, L. F., Bohn, J. A., & Benbrook, D. M. (2025) · Biomedicines · doi:10.3390/biomedicines13092074 · Cited by 2
Calanca, N., Rainho, C. A., Maeda, D. K., Côrtes, L., Villacis, R. A. R., Bizinelli, D., Kuasne, H., Aagaard, M. M., Fokdal, L. U., Steffensen, K. D., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118668 · Cited by 2
Doppel as an early‐stage biomarker promoting EMT and dissemination in ovarian cancers
Azam, Z., Zhang, X., Wahab, R., Hasan, M. M., Dhadhal, S., Kang, B., Hassan, M. M., Karim, M., Choi, J. U., Rana, M., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.70268 · Cited by 2
Yang, L., He, T., Wang, J., Zhang, X., Zeng, L., Sun, Q., Song, Y., Nie, Y., Gao, X., Shang, C., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1698793 · Cited by 2
Estrada, M. F., Amorim, F., da Silva, F. F., de Almeida, C. R., Fontes, M., Coelho, R., Ferreira, S., Canas‐Marques, R., Castillo-Martín, M., Casanova, J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102530 · Cited by 2
Wang, C., Chu, T.-C., Wu, T.-K., Chung, Y.-P., Lin, S.-S., & Chao, T.-K. (2026) · npj Digital Medicine · doi:10.1038/s41746-026-02359-1 · Cited by 4
Mortan, L. F., Isingizwe, Z. R., & Benbrook, D. M. (2026) · Cells · doi:10.3390/cells15030267 · Cited by 2
Jiang, R., Yu, Y., Guan, J., Ma, J., Qiu, H., Zhong, J., Liu, N., Zhao, H., Zheng, Y., & Du, Y. (2026) · Seminars in Oncology · doi:10.1016/j.seminoncol.2026.152470 · Cited by 3
Cheng, S., Kolendowski, B., Ramos-Valdes, Y., Shepherd, T. G., & DiMattia, G. E. (2026) · Cells · doi:10.3390/cells15080673 · Cited by 2
Miyamoto, T., Ye, Y., Soliman, M. M. H., Manning, B. S., Murphy, B., Zhu, L., Shao, C., Mirji, G., Minakuchi, M., Hamada, K., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014253 · Cited by 2
Ovarian cancer, malignant ascites and microenvironment. Literature review
Aleshikova, O. I., Babaeva, N. A., Викторовна, Г. Е., Antonova, I. B., Shender, V. О., Babaeva, A. E., & Ashrafyan, L. А. (2023) · Sechenov Medical Journal · doi:10.47093/2218-7332.2023.14.2.21-30 · Cited by 2
Chitcholtan, K., Dyer, A., & Sykes, P. H. (2023) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/j.ceog5010212 · Cited by 2
Loss of B1 and marginal zone B cells during ovarian cancer
Maslanka, J. R., Torres, G. M., Londregan, J., Goldman, N., Silberman, D., Somerville, J. E., & Riggs, J. E. (2023) · Cellular Immunology · doi:10.1016/j.cellimm.2023.104788 · Cited by 2
Constantinescu, D., Sorop, A., Ghionescu, A.-V., Lixandru, D., Herlea, V., Bacalbașa, N., & Dima, S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1363142 · Cited by 2
Dietze, R., Szymanski, W. G., Ojasalu, K., Finkernagel, F., Nist, A., Stiewe, T., Graumann, J., & Müller, R. (2024) · Cells · doi:10.3390/cells13100810 · Cited by 2
Liu, S. (2024) · American Journal of Cancer Research · doi:10.62347/onuy8904 · Cited by 2
Phenotypic evaluation of the ovarian tumor cells presents in malignant ascites
Ferreira, S. D. C., Nunes, M., Nunes, D., & Ricardo, S. A. V. (2022) · RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia · doi:10.51126/revsalus.v4isup.319 · Cited by 2
Prabowo, A., Tjokroprawiro, B. A., & Utomo, B. (2022) · Bali Medical Journal · doi:10.15562/bmj.v11i2.3575 · Cited by 2
Jinekolojik Kanser Hastalarında Giderek Artan Gereksinim: Palyatif Bakım
Büyükokudan, Ş., & Körükcü, Ö. (2023) · Izmir Democracy University Health Sciences Journal · doi:10.52538/iduhes.1218561 · Cited by 1
(2023) · European Journal of Gynaecological Oncology · doi:10.22514/ejgo.2023.078 · Cited by 1
Future perspective: identification and validation of biomarkers using liquid biopsy
Kashyap, S., Nadhan, R., Jayaraman, M., Gomathinayagam, R., Ha, J. H., & Dhanasekaran, D. N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-824040-3.00013-3 · Cited by 1
Clonal evolution and molecular mechanisms of ovarian cancer: a comprehensive review
Nagasaka, K. (2024) · Academia oncology. · doi:10.20935/acadonco7484 · Cited by 1
Cortesi, M., Liu, D., Powell, E., Barlow, E. L., Warton, K., Giordano, E., & Ford, C. E. (2025) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70082 · Cited by 1
Yu, F., Zhou, Q., Yu, W., Zhou, T., Cao, C., Xie, Y., Zhang, P., Liu, H., He, W., Cheng, A., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02546-w · Cited by 3
Cortesi, M., Li, J., Liu, D., Guo, T., Dokos, S., Warton, K., & Ford, C. E. (2026) · Biophysics Reviews · doi:10.1063/5.0293339 · Cited by 1
Li, Q., Zhang, Y., Luo, H., Wu, Y., Qin, J., Wang, L., Zhang, Q., Yu, T., Huang, X., Guo, S., et al. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00452-2 · Cited by 2
Roma Index and Adnex Model: which is more Superior in Predicting Epithelial Ovarian Malignancy?
Lumandung, F. T., Mongan, S. P., & Laihad, B. J. (2023) · Indonesian Journal of Obstetrics and Gynecology · doi:10.32771/inajog.v11i3.1819 · Cited by 1
Pires, M. R., Estrada, M. F., Gomes, A. P., Silva, F., Baptista, C., Ramos, M. J., Fortuna, A., Simões, P., Sousa, G. A., Marreiros, A., et al. (2023) · Cancers · doi:10.3390/cancers16010162 · Cited by 1
Balakrishnan, P., Shah, J., Surmava, S., Kvaratskhelia, E., Abzianidze, E., Vardiashvili, N., & Kankava, K. (2024) · Scripta Medica · doi:10.5937/scriptamed55-47930 · Cited by 1
Li, H., Xiao, J., & Tian, M. (2024) · Oncology Letters · doi:10.3892/ol.2024.14790 · Cited by 1
Iyoshi, S., Sunohara, M., Yoshihara, M., Kunishima, A., Miyamoto, E., Fujimoto, H., Kitami, K., Mogi, K., Uno, K., Yoshida, K., et al. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf046 · Cited by 1
Ogawa, R., Ohe, R., Kitaoka, T., Ohta, T., Nagase, S., & Futakuchi, M. (2025) · Journal of Cytology · doi:10.4103/joc.joc_152_24 · Cited by 1
Ovarian Cancer Stem Cells and Their Regulatory Mechanisms: Potential Targets for Therapy
Parte, S. C., Ponnusamy, M. P., Batra, S. K., & Kakar, S. S. (2022) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-030-90111-0_4 · Cited by 1
Luo, N., Sulaiman, Z., Wang, C., Ding, J., Chen, Y., Liu, B., Cheng, Z., & Liu, S. (2022) · Research Square · doi:10.21203/rs.3.rs-1401444/v1 · Cited by 1
Sussman, D., & Tannenbaum, E. (2022) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.28447 · Cited by 1
Water in the Belly- a Review of Current Knowledge About Ascites in ChildrenPreprint
Kamińska, A., Plata‐Nazar, K., & Leszkowicz, J. (2023) · Preprints.org · doi:10.20944/preprints202306.2262.v1 · Cited by 1
Immunotherapy for ovarian cancer is improved by tumor-targeted delivery of a neoantigen surrogatePreprint
Scanlon, L., Gabor, L. R., Khouri, O. R., Ahmad, S., Levy, E., Buckley, E., Ouedraogo, A., Kuo, D. Y., Lin, K. Y., Nevadunsky, N. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.11.561944 · Cited by 1
Zhang, K., Kahelin, E., Marchi, G., Lehtonen, O., Salloum, S., Lavikka, K., Li, Y., Dietlein, F., Lahtinen, A., Oikkonen, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.26.672372 · Cited by 1
Metadata
- Authors
- Ford, C. E., Werner, B., Hacker, N. F., & Warton, K.
- Affiliations
- UNSW Sydney (AU)
- Corresponding author
- Ford, Caroline Elizabeth
- Venue
- British Journal of Cancer
- Published
- 2020-05-08
- Volume
- 123
- Issue
- 1
- Pages
- 9-16
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC7341795
- OpenAlex
- W3022087601
- Cited by
- 261
- References
- 110
- Citations by year
- 2026: 44 · 2025: 51 · 2024: 60 · 2023: 46 · 2022: 42 · 2021: 18
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- British Journal of Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Translational Cancer Research Network
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- ascites, ovarian cancer, peritoneal carcinomatosis, chemoresistance, translational research
- MeSH terms
- Ascites, Female, Humans, Ovarian Neoplasms, Ovary, Biomarkers, Tumor, Proteomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
